BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Danese S, Sandborn WJ, Colombel J, Vermeire S, Glover SC, Rimola J, Siegelman J, Jones S, Bornstein JD, Feagan BG. Endoscopic, Radiologic, and Histologic Healing With Vedolizumab in Patients With Active Crohn’s Disease. Gastroenterology 2019;157:1007-1018.e7. [DOI: 10.1053/j.gastro.2019.06.038] [Cited by in Crossref: 59] [Cited by in F6Publishing: 53] [Article Influence: 19.7] [Reference Citation Analysis]
Number Citing Articles
1 Xu L, Shen J, Zheng Q. Development of a clinical model to predict secondary non-response of infliximab treatment in Crohn's disease. Int J Colorectal Dis 2020;35:2019-26. [PMID: 32577870 DOI: 10.1007/s00384-020-03679-8] [Cited by in Crossref: 1] [Article Influence: 0.5] [Reference Citation Analysis]
2 Bossuyt P, Dreesen E, Rimola J, Devuysere S, De Bruecker Y, Vanslembrouck R, Laurent V, Zappa M, Savoye-collet C, Pariente B, Filippi J, Baert F, D’haens G, Laharie D, Peyrin-biroulet L, Vermeire S, Lambrecht G, Buisson A, Bouhnik Y, Woude JV, Van Hootegem P, Moreau J, Louis E, Franchimont D, De Vos M, Mana F, Brixi H, Allez M, Caenepeel P, Aubourg A, Oldenburg B, Pierik M, Chevret S. Infliximab Exposure Associates With Radiologic Evidence of Healing in Patients With Crohn’s Disease. Clinical Gastroenterology and Hepatology 2021;19:947-954.e2. [DOI: 10.1016/j.cgh.2020.04.052] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
3 Farias e Silva K, Nanini HF, Cascabulho CM, Rosas SLB, Santana PT, Carneiro AJV, Anaissie E, Nucci M, de Souza HSP. Serum 1,3-beta-D-glucan as a noninvasive test to predict histologic activity in patients with inflammatory bowel disease. World J Gastroenterol 2021; 27(9): 866-885 [PMID: 33727775 DOI: 10.3748/wjg.v27.i9.866] [Reference Citation Analysis]
4 Rimola J, Fernàndez-Clotet A, Capozzi N, Rojas-Farreras S, Alfaro I, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J. Pre-treatment magnetic resonance enterography findings predict the response to TNF-alpha inhibitors in Crohn's disease. Aliment Pharmacol Ther 2020;52:1563-73. [PMID: 32886809 DOI: 10.1111/apt.16069] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
5 Verstockt B, Mertens E, Dreesen E, Outtier A, Noman M, Tops S, Schops G, Van Assche G, Vermeire S, Gils A, Ferrante M. Influence of Drug Exposure on Vedolizumab-Induced Endoscopic Remission in Anti-Tumour Necrosis Factor [TNF] Naïve and Anti-TNF Exposed IBD Patients. Journal of Crohn's and Colitis 2020;14:332-41. [DOI: 10.1093/ecco-jcc/jjz151] [Cited by in Crossref: 13] [Cited by in F6Publishing: 12] [Article Influence: 4.3] [Reference Citation Analysis]
6 Crooks B, Barnes T, Limdi JK. Vedolizumab in the treatment of inflammatory bowel disease: evolving paradigms. Drugs Context. 2020;9:2019-10. [PMID: 32180822 DOI: 10.7573/dic.2019-10-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
7 Bor R, Fábián A, Matuz M, Szepes Z, Farkas K, Miheller P, Szamosi T, Vincze Á, Rutka M, Szántó K, Bálint A, Nagy F, Milassin Á, Tóth T, Zsigmond F, Bajor J, Müllner K, Lakner L, Papp M, Salamon Á, Horváth G, Sarang K, Schäfer E, Sarlós P, Palatka K, Molnár T. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease – A nationwide Hungarian cohort study. Expert Opinion on Biological Therapy 2020;20:205-13. [DOI: 10.1080/14712598.2020.1699529] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.7] [Reference Citation Analysis]
8 White JR, Din S, Ingram RJM, Foley S, Alam MA, Robinson R, Francis R, Tucker E, Jalal M, Elphick D, Atallah E, Norman A, Amin M, Sajjad A, Heggs N, Meadowcroft S, Moran GW. Experiences of using vedolizumab in the treatment of inflammatory bowel disease in the East Midlands UK – a retrospective observational study. Scandinavian Journal of Gastroenterology 2020;55:907-16. [DOI: 10.1080/00365521.2020.1790647] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
9 Narula N, Wong ECL, Colombel JF, Sandborn WJ, Ferrante M, Marshall JK, Reinisch W, Dulai PS. Early Reduction in MM-SES-CD Score After Initiation of Biologic Therapy is Highly Specific for One-Year Endoscopic Remission in Moderate to Severe Crohn's Disease. J Crohns Colitis 2021:jjab183. [PMID: 34664635 DOI: 10.1093/ecco-jcc/jjab183] [Reference Citation Analysis]
10 Watanabe K, Motoya S, Ogata H, Kanai T, Matsui T, Suzuki Y, Shikamura M, Sugiura K, Oda K, Hori T, Araki T, Watanabe M, Hibi T. Effects of vedolizumab in Japanese patients with Crohn's disease: a prospective, multicenter, randomized, placebo-controlled Phase 3 trial with exploratory analyses. J Gastroenterol. 2020;55:291-306. [PMID: 31836930 DOI: 10.1007/s00535-019-01647-w] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 3.0] [Reference Citation Analysis]
11 Danese S, Subramaniam K, Van Zyl J, Adsul S, Lindner D, Roth J, Vermeire S. Vedolizumab treatment persistence and safety in a 2-year data analysis of an extended access programme. Aliment Pharmacol Ther 2021;53:265-72. [PMID: 33210333 DOI: 10.1111/apt.16160] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Dal Buono A, Roda G, Argollo M, Zacharopoulou E, Peyrin-Biroulet L, Danese S. Treat to target or 'treat to clear' in inflammatory bowel diseases: one step further? Expert Rev Gastroenterol Hepatol 2020;14:807-17. [PMID: 32762582 DOI: 10.1080/17474124.2020.1804361] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
13 Ho GT, Cartwright JA, Thompson EJ, Bain CC, Rossi AG. Resolution of Inflammation and Gut Repair in IBD: Translational Steps Towards Complete Mucosal Healing. Inflamm Bowel Dis 2020;26:1131-43. [PMID: 32232386 DOI: 10.1093/ibd/izaa045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 17] [Article Influence: 16.0] [Reference Citation Analysis]
14 Wilkens R, Novak KL, Maaser C, Panaccione R, Kucharzik T. Relevance of monitoring transmural disease activity in patients with Crohn's disease: current status and future perspectives. Therap Adv Gastroenterol 2021;14:17562848211006672. [PMID: 33948115 DOI: 10.1177/17562848211006672] [Reference Citation Analysis]
15 Meserve J, Dulai P. Predicting Response to Vedolizumab in Inflammatory Bowel Disease. Front Med (Lausanne) 2020;7:76. [PMID: 32300596 DOI: 10.3389/fmed.2020.00076] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
16 Tao Y, Li H, Xu H, Tang W, Fan G, Yang X. Can the simplified magnetic resonance index of activity be used to evaluate the degree of activity in Crohn's disease? BMC Gastroenterol 2021;21:409. [PMID: 34711180 DOI: 10.1186/s12876-021-01987-z] [Reference Citation Analysis]
17 King JR, Grover Z, Irani N, Mclean-tooke A. Vedolizumab is safe and effective in the treatment of X-linked agammaglobulinemia–associated inflammatory bowel disease. The Journal of Allergy and Clinical Immunology: In Practice 2021;9:1006-7. [DOI: 10.1016/j.jaip.2020.11.040] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
18 Pauwels RWM, de Vries AC, van der Woude CJ. Fecal calprotectin is a reliable marker of endoscopic response to vedolizumab therapy: A simple algorithm for clinical practice. J Gastroenterol Hepatol 2020;35:1893-901. [PMID: 32291796 DOI: 10.1111/jgh.15063] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
19 Hanzel J, Dreesen E, Vermeire S, Löwenberg M, Hoentjen F, Bossuyt P, Clasquin E, Baert FJ, D'Haens GR, Mathôt R. Pharmacokinetic-Pharmacodynamic Model of Vedolizumab for Targeting Endoscopic Remission in Patients With Crohn Disease: Posthoc Analysis of the LOVE-CD Study. Inflamm Bowel Dis 2021:izab143. [PMID: 34137430 DOI: 10.1093/ibd/izab143] [Reference Citation Analysis]
20 Attauabi M, Madsen GR, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as the first line of biologic therapy for ulcerative colitis and Crohn's disease - a systematic review with meta-analysis. Dig Liver Dis 2021:S1590-8658(21)00856-2. [PMID: 34903497 DOI: 10.1016/j.dld.2021.11.014] [Reference Citation Analysis]
21 Cao WT, Huang R, Jiang KF, Qiao XH, Wang JJ, Fan YH, Xu Y. Predictive value of blood concentration of biologics on endoscopic inactivity in inflammatory bowel disease: A systematic review. World J Gastroenterol 2021; 27(9): 886-907 [PMID: 33727776 DOI: 10.3748/wjg.v27.i9.886] [Reference Citation Analysis]
22 Bozward AG, Ronca V, Osei-Bordom D, Oo YH. Gut-Liver Immune Traffic: Deciphering Immune-Pathogenesis to Underpin Translational Therapy. Front Immunol 2021;12:711217. [PMID: 34512631 DOI: 10.3389/fimmu.2021.711217] [Reference Citation Analysis]
23 Fernàndez-Clotet A, Sapena V, Capozzi N, Rodríguez S, Masamunt MC, Ricart E, Ordás I, Panés J, Rimola J. Avoiding contrast-enhanced sequences does not compromise the precision of the simplified MaRIA for the assessment of non-penetrating Crohn's disease activity. Eur Radiol 2022. [PMID: 35031844 DOI: 10.1007/s00330-021-08392-w] [Reference Citation Analysis]
24 Marion L, Amélie B, Zoubir D, Guillaume C, Elise M, Hedia B, Margaux LS, Aude M, Camille B. Histological Indices and Risk of Recurrence in Crohn’s Disease: A Retrospective Study of a Cohort of Patients in Endoscopic Remission. Inflammatory Bowel Diseases 2022. [DOI: 10.1093/ibd/izac074] [Reference Citation Analysis]
25 Nuñez F P, Mahadevan U, Quera R, Bay C, Ibañez P. Treat-to-target approach in the management of inflammatory Bowel disease. Gastroenterol Hepatol 2021;44:312-9. [PMID: 33070988 DOI: 10.1016/j.gastrohep.2020.06.032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
26 Christensen B, Rubin DT. Reply. Clin Gastroenterol Hepatol 2021;19:2452-4. [PMID: 33278575 DOI: 10.1016/j.cgh.2020.11.044] [Reference Citation Analysis]
27 Tyler CJ, Guzman M, Lundborg LR, Yeasmin S, Perez-Jeldres T, Yarur A, Behm B, Dulai PS, Patel D, Bamias G, Rivera-Nieves J. Inherent Immune Cell Variation Within Colonic Segments Presents Challenges for Clinical Trial Design. J Crohns Colitis 2020;14:1364-77. [PMID: 32239151 DOI: 10.1093/ecco-jcc/jjaa067] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Yao J, Jiang Y, Ke J, Lu Y, Hu J, Zhi M. A Validated Prognostic Model and Nomogram to Predict Early-Onset Complications Leading to Surgery in Patients With Crohn's Disease. Dis Colon Rectum 2021;64:697-705. [PMID: 33315712 DOI: 10.1097/DCR.0000000000001881] [Reference Citation Analysis]
29 Feagan BG, Sandborn WJ, Danese S, Wolf DC, Liu WJ, Hua SY, Minton N, Olson A, D'Haens G. Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study. Lancet Gastroenterol Hepatol 2020;5:819-28. [PMID: 32553149 DOI: 10.1016/S2468-1253(20)30188-6] [Cited by in Crossref: 21] [Cited by in F6Publishing: 9] [Article Influence: 10.5] [Reference Citation Analysis]
30 Coelho-Prabhu N, Kane S. Does Size Really Matter? Am J Gastroenterol 2021;116:84-5. [PMID: 33181520 DOI: 10.14309/ajg.0000000000001057] [Reference Citation Analysis]
31 Geyl S, Guillo L, Laurent V, D'Amico F, Danese S, Peyrin-Biroulet L. Transmural healing as a therapeutic goal in Crohn's disease: a systematic review. Lancet Gastroenterol Hepatol 2021;6:659-67. [PMID: 34090579 DOI: 10.1016/S2468-1253(21)00096-0] [Reference Citation Analysis]
32 Cucchiara S, D'Arcangelo G, Isoldi S, Aloi M, Stronati L. Mucosal healing in Crohn's disease: new insights. Expert Rev Gastroenterol Hepatol. 2020;14:335-345. [PMID: 32315209 DOI: 10.1080/17474124.2020.1759416] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
33 Debnath P, Rathi P. Treat to Target in Patients with Ileocolonic Crohn's Disease: Endoscopic Remission or Histologic Healing? Clin Gastroenterol Hepatol 2021;19:2452. [PMID: 33248107 DOI: 10.1016/j.cgh.2020.10.042] [Reference Citation Analysis]
34 Garcia-Romero R, Martinez de Zabarte Fernandez JM, Pujol-Muncunill G, Donat-Aliaga E, Segarra-Cantón O, Irastorza-Terradillos I, Medina-Benitez E, Ruiz-Hernández CJ, Carrillo-Palau M, Ros-Arnal I, Rodriguez-Martínez A, Escartin-Madurga L, Gutiérrez-Junquera C, Vicente-Santamaría S, Velasco Rodriguez-Belvis M, Fernández-Fernández S, Alberto-Alonso JR, Montraveta M, Torres-Peral R, Navalon-Rubio M, Navas-López VM, Martin de Carpi J. Safety and effectiveness of vedolizumab in paediatric patients with inflammatory bowel disease: an observational multicentre Spanish study. Eur J Pediatr 2021;180:3029-38. [PMID: 33880650 DOI: 10.1007/s00431-021-04063-6] [Reference Citation Analysis]
35 Gonczi L, Bessissow T, Lakatos PL. Ver(s)ifying the Efficacy of Vedolizumab Therapy on Mucosal Healing in Patients With Crohn's Disease. Gastroenterology 2019;157:925-7. [PMID: 31356804 DOI: 10.1053/j.gastro.2019.07.032] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.7] [Reference Citation Analysis]
36 Pierre N, Salée C, Vieujean S, Bequet E, Merli AM, Siegmund B, Meuwis MA, Louis E. Review article: distinctions between ileal and colonic Crohn's disease: from physiology to pathology. Aliment Pharmacol Ther 2021;54:779-91. [PMID: 34297423 DOI: 10.1111/apt.16536] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
37 Bertani L, Caviglia GP, Antonioli L, Pellicano R, Fagoonee S, Astegiano M, Saracco GM, Bugianesi E, Blandizzi C, Costa F, Ribaldone DG. Serum Interleukin-6 and -8 as Predictors of Response to Vedolizumab in Inflammatory Bowel Diseases. J Clin Med 2020;9:E1323. [PMID: 32370274 DOI: 10.3390/jcm9051323] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 3.5] [Reference Citation Analysis]
38 Venkatapurapu SP, Iwakiri R, Udagawa E, Patidar N, Qi Z, Takayama R, Kumar K, Sato Y, Behar M, Offner P, Dwivedi G, Miyasaka H, Suzuki RK, Hamada AL, D'Alessandro PM, Fernandez J. A Computational Platform Integrating a Mechanistic Model of Crohn's Disease for Predicting Temporal Progression of Mucosal Damage and Healing. Adv Ther 2022. [PMID: 35581423 DOI: 10.1007/s12325-022-02144-y] [Reference Citation Analysis]
39 Plevris N, Lees CW. Disease Monitoring in Inflammatory Bowel Disease: Evolving Principles and Possibilities. Gastroenterology 2022:S0016-5085(22)00078-6. [PMID: 35101422 DOI: 10.1053/j.gastro.2022.01.024] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
40 Wu Y, Wang Z, Xing M, Li B, Liu Z, Du P, Yang H, Wang X. The Specific Changes of Urine Raman Spectra Can Serve as Novel Diagnostic Tools for Disease Characteristics in Patients with Crohn’s Disease. JIR 2022;Volume 15:897-910. [DOI: 10.2147/jir.s341871] [Reference Citation Analysis]
41 Vermeire S, D'Haens G, Baert F, Danese S, Kobayashi T, Loftus EV Jr, Bhatia S, Agboton C, Rosario M, Chen C, Zhang W, Kisfalvi K, Sandborn WJ. Efficacy and Safety of Subcutaneous Vedolizumab in Patients With Moderately to Severely Active Crohn's Disease: Results From the VISIBLE 2 Randomised Trial. J Crohns Colitis 2021:jjab133. [PMID: 34402887 DOI: 10.1093/ecco-jcc/jjab133] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
42 Scarozza P, De Cristofaro E, Scucchi L, Rocchetti I, Marafini I, Neri B, Salvatori S, Biancone L, Calabrese E, Monteleone G. Effect of Vedolizumab on Anemia of Chronic Disease in Patients with Inflammatory Bowel Diseases. J Clin Med 2020;9:E2126. [PMID: 32640680 DOI: 10.3390/jcm9072126] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
43 Gamliel A, Werner L, Pinsker M, Salamon N, Weiss B, Shouval DS. Circulating α4β7+ Memory T Cells in Pediatric IBD Patients Express a Polyclonal T Cell Receptor Repertoire. Clin Exp Gastroenterol 2020;13:439-47. [PMID: 33061522 DOI: 10.2147/CEG.S271565] [Reference Citation Analysis]
44 Wu Y, Zhang L, Cao J, Wang H, Ye C, Zhuoma D, Yang P, Wang X. Efficacy of infliximab treatment on the mucosal healing of different intestinal segments in patients with ileocolonic Crohn's disease. Therap Adv Gastroenterol 2020;13:1756284820976923. [PMID: 33425009 DOI: 10.1177/1756284820976923] [Reference Citation Analysis]
45 Alkhatry M, Al-Rifai A, Annese V, Georgopoulos F, Jazzar AN, Khassouan AM, Koutoubi Z, Nathwani R, Taha MS, Limdi JK. First United Arab Emirates consensus on diagnosis and management of inflammatory bowel diseases: A 2020 Delphi consensus. World J Gastroenterol 2020; 26(43): 6710-6769 [PMID: 33268959 DOI: 10.3748/wjg.v26.i43.6710] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
46 Christensen B, Erlich J, Gibson PR, Turner JR, Hart J, Rubin DT. Histologic Healing Is More Strongly Associated with Clinical Outcomes in Ileal Crohn's Disease than Endoscopic Healing. Clin Gastroenterol Hepatol 2020; 18: 2518-2525. e1. [PMID: 31812654 DOI: 10.1016/j.cgh.2019.11.056] [Cited by in Crossref: 20] [Cited by in F6Publishing: 17] [Article Influence: 6.7] [Reference Citation Analysis]
47 Atreya R, Bojarski C, Kühl AA, Trajanoski Z, Neurath MF, Siegmund B. Ileal and colonic Crohn'´s disease: Ddoes location makes a difference in therapy efficacy? Current Research in Pharmacology and Drug Discovery 2022. [DOI: 10.1016/j.crphar.2022.100097] [Reference Citation Analysis]
48 Li XZ, Qiu Y, Jeffery L, Liu F, Feng R, He JS, Tan JY, Ye ZY, Lin SN, Ghosh S, Iacucci M, Chen MH, Mao R. Down-Regulation of Colonic ACE2 Expression in Patients With Inflammatory Bowel Disease Responding to Anti-TNF Therapy: Implications for COVID-19. Front Med (Lausanne) 2020;7:613475. [PMID: 33511147 DOI: 10.3389/fmed.2020.613475] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
49 Wu S, Zeng L, Li W, Wu YT, Jing JG, Zhuang H, Wang YF. The value of multi-modes of ultrasound in evaluating segmental mucosal healing in patients with Crohn's disease. Dig Liver Dis 2022:S1590-8658(21)00896-3. [PMID: 34991975 DOI: 10.1016/j.dld.2021.12.009] [Reference Citation Analysis]
50 Cazzato G, Colagrande A, Andriola V, Lettini T, Cicco S, Candance PMV, Resta L, Vincenti L, Ingravallo G. Histological Hallmarks of Mucosal Healing in Inflammatory Bowel Diseases in the Era of Monoclonal Antibodies Therapy: New Insights and Perspectives. Diagnostics (Basel) 2021;11:1570. [PMID: 34573912 DOI: 10.3390/diagnostics11091570] [Reference Citation Analysis]
51 Volkers A, Bossuyt P, de Jong J, Pouillon L, Gecse K, Duijvestein M, Ponsioen C, D'Haens G, Löwenberg M. Assessment of endoscopic response using pan-enteric capsule endoscopy in Crohn's disease; the Sensitivity to Change (STOC) study. Scand J Gastroenterol 2021;:1-7. [PMID: 34968158 DOI: 10.1080/00365521.2021.2018491] [Reference Citation Analysis]
52 Debnath P, Rathi PM. Vedolizumab in Inflammatory Bowel Disease: West versus East. Inflamm Intest Dis 2021;6:1-17. [PMID: 33850834 DOI: 10.1159/000512805] [Reference Citation Analysis]
53 Luzentales-Simpson M, Pang YCF, Zhang A, Sousa JA, Sly LM. Vedolizumab: Potential Mechanisms of Action for Reducing Pathological Inflammation in Inflammatory Bowel Diseases. Front Cell Dev Biol 2021;9:612830. [PMID: 33614645 DOI: 10.3389/fcell.2021.612830] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
54 Romero RK, Magro DO, Queiroz NSF, Damião AOMC, Teixeira FV, Nones RB, Sassaki LY, Saad-Hossne R, Kotze PG. Perception and clinical decisions from inflammatory bowel diseases' specialists towards positioning of new therapies in Crohn's disease and ulcerative colitis: A national web-based survey from the Brazilian IBD study group (GEDIIB). Gastroenterol Hepatol 2021:S0210-5705(21)00296-X. [PMID: 34634427 DOI: 10.1016/j.gastrohep.2021.09.005] [Reference Citation Analysis]
55 Vermeire S, Lukáš M, Magro F, Adsul S, Lindner D, Rosario M, Roth J, Danese S. Vedolizumab Efficacy, Safety, and Pharmacokinetics With Reduced Frequency of Dosing From Every 4 Weeks to Every 8 Weeks in Patients With Crohn's Disease or Ulcerative Colitis. J Crohns Colitis 2020;14:1066-73. [PMID: 32060515 DOI: 10.1093/ecco-jcc/jjaa027] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
56 Atreya R, Siegmund B. Location is important: differentiation between ileal and colonic Crohn's disease. Nat Rev Gastroenterol Hepatol 2021;18:544-58. [PMID: 33712743 DOI: 10.1038/s41575-021-00424-6] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
57 Dulai PS, Amiot A, Peyrin-Biroulet L, Jairath V, Serrero M, Filippi J, Singh S, Pariente B, Loftus EV Jr, Roblin X, Kane S, Buisson A, Siegel CA, Bouhnik Y, Sandborn WJ, Lasch K, Rosario M, Feagan BG, Bojic D, Trang-Poisson C, Shen B, Altwegg R, Sands BE, Colombel JF, Carbonnel F; GETAID OBSERV-IBD, VICTORY Cohorts Collaboration*. A clinical decision support tool may help to optimise vedolizumab therapy in Crohn's disease. Aliment Pharmacol Ther 2020;51:553-64. [PMID: 31867766 DOI: 10.1111/apt.15609] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 3.7] [Reference Citation Analysis]
58 Limdi JK, Picco M, Farraye FA. A review of endoscopic scoring systems and their importance in a treat-to-target approach in inflammatory bowel disease (with videos). Gastrointestinal Endoscopy 2020;91:733-45. [DOI: 10.1016/j.gie.2019.11.032] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 6.5] [Reference Citation Analysis]
59 Pagnini C, Di Paolo MC, Giordano M, Graziani MG. Histologic disease activity control as a therapeutic target in Crohn's disease patients: A word of caution. Dig Liver Dis 2020;52:591-2. [PMID: 32057685 DOI: 10.1016/j.dld.2020.01.003] [Reference Citation Analysis]
60 Zingone F, Barberio B, Compostella F, Girardin G, D'Incà R, Marinelli C, Marsilio I, Lorenzon G, Savarino EV. Good efficacy and safety of vedolizumab in Crohn's disease and ulcerative colitis in a real-world scenario. Therap Adv Gastroenterol 2020;13:1756284820936536. [PMID: 32695231 DOI: 10.1177/1756284820936536] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 1.5] [Reference Citation Analysis]
61 Wlazło M, Kierkuś J. Dual Biologic Therapy for the Treatment of Pediatric Inflammatory Bowel Disease: A Review of the Literature. JCM 2022;11:2004. [DOI: 10.3390/jcm11072004] [Reference Citation Analysis]
62 Hyun HK, Yu J, Kang EA, Park J, Park SJ, Park JJ, Kim TI, Kim WH, Cheon JH. Radiology plus ileocolonoscopy versus radiology alone in Crohn's disease: prognosis prediction and mutual agreement. Korean J Intern Med 2021. [PMID: 34695881 DOI: 10.3904/kjim.2021.233] [Reference Citation Analysis]
63 Akbar A, Orchard T, Powell N, Selinger C, tibbatts C. Influence of comorbidities on treatment considerations for first-line biologic prescribing in patients with inflammatory bowel disease in the UK. Frontline Gastroenterol. [DOI: 10.1136/flgastro-2021-101995] [Reference Citation Analysis]
64 Scarozza P, Marafini I, Laudisi F, Troncone E, Schmitt H, Lenti MV, Costa S, Rocchetti I, De Cristofaro E, Salvatori S, Frezzati L, Di Sabatino A, Atreya R, Neurath MF, Calabrese E, Monteleone G. Extent of Mucosal Inflammation in Ulcerative Colitis Influences the Clinical Remission Induced by Vedolizumab. J Clin Med 2020;9:E385. [PMID: 32024071 DOI: 10.3390/jcm9020385] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
65 D'Amico F, Baumann C, Rousseau H, Danese S, Peyrin-Biroulet L. Phase I, II and III Trials in Inflammatory Bowel Diseases: A Practical Guide for the Non-specialist. J Crohns Colitis 2020;14:710-8. [PMID: 31901097 DOI: 10.1093/ecco-jcc/jjz214] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
66 Narula N, Wong ECL, Aruljothy A, Dulai PS, Colombel JF, Marshall JK, Ferrante M, Reinisch W. Ileal and Rectal Ulcer Size Affects the Ability to Achieve Endoscopic Remission: A Post hoc Analysis of the SONIC Trial. Am J Gastroenterol 2020;115:1236-45. [PMID: 32759621 DOI: 10.14309/ajg.0000000000000617] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 2.0] [Reference Citation Analysis]
67 Deepak P, Ludwig DR, Fidler JL, Guglielmo FF, Bruining DH. Medical and Endoscopic Management of Crohn Disease. Top Magn Reson Imaging 2021;30:43-61. [PMID: 33528211 DOI: 10.1097/RMR.0000000000000267] [Reference Citation Analysis]
68 Watanabe K. Clinical management for small bowel of Crohn's disease in the treat-to-target era: now is the time to optimize treatment based on the dominant lesion. Intest Res. 2020;18:347-354. [PMID: 33131231 DOI: 10.5217/ir.2020.00032] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.5] [Reference Citation Analysis]
69 Macaluso FS, Castiglione F, Rispo A, Orlando A. The VERSIFY Trial: What About Ultrasound Assessment? Gastroenterology 2020;158:1176-7. [PMID: 31836531 DOI: 10.1053/j.gastro.2019.11.298] [Reference Citation Analysis]
70 Nakase H, Uchino M, Shinzaki S, Matsuura M, Matsuoka K, Kobayashi T, Saruta M, Hirai F, Hata K, Hiraoka S, Esaki M, Sugimoto K, Fuji T, Watanabe K, Nakamura S, Inoue N, Itoh T, Naganuma M, Hisamatsu T, Watanabe M, Miwa H, Enomoto N, Shimosegawa T, Koike K. Evidence-based clinical practice guidelines for inflammatory bowel disease 2020. J Gastroenterol 2021;56:489-526. [PMID: 33885977 DOI: 10.1007/s00535-021-01784-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 4] [Article Influence: 8.0] [Reference Citation Analysis]
71 Arebi N. Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice? Lancet Gastroenterol Hepatol 2020;5:877-8. [PMID: 32619414 DOI: 10.1016/S2468-1253(20)30234-X] [Reference Citation Analysis]
72 Attauabi M, Höglund C, Fassov J, Pedersen KB, Hansen HB, Wildt S, Jensen MD, Neumann A, Lind C, Jacobsen HA, Popa AM, Kjeldsen J, Pedersen N, Molazahi A, Haderslev K, Aalykke C, Knudsen T, Cebula W, Munkholm P, Bendtsen F, Seidelin JB, Burisch J. Vedolizumab as first-line biological therapy in elderly patients and those with contraindications for anti-TNF therapy: a real-world, nationwide cohort of patients with inflammatory bowel diseases. Scand J Gastroenterol 2021;56:1040-8. [PMID: 34224299 DOI: 10.1080/00365521.2021.1946588] [Reference Citation Analysis]
73 Klemm N, Trasolini R, Chahal D, Donnellan F. Vedolizumab for steroid & infliximab refractory immune checkpoint inhibitor associated colitis. Clin Res Hepatol Gastroenterol. 2021;45:101604. [PMID: 33454238 DOI: 10.1016/j.clinre.2020.101604] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]